The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Critical reviews in oncology/hematology

• Publication date

  2017-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.critrevonc.2017.01.002PMID 28259298
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abstract B20: The necrosome promotes pancreatic Oncogenesis via CXCL1 and mincle-induced immune Suppression

  2016cited by this paper
• Modeling pancreatic cancer with organoids.

  2016cited by this paper
• GNASR201H and KrasG12D cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm

  2016cited by this paper
• KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma

  2016cited by this paper
• Abstract PR01: Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell and patient-derived tumor organoids

  2016cited by this paper
• A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.

  2016cited by this paper
• Genomic analyses identify molecular subtypes of pancreatic cancer

  2016cited by this paper
• NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer.

  2016cited by this paper
• Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.

  2016cited by this paper
• Current progress in immunotherapy for pancreatic cancer.

  2016cited by this paper
• Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation

  2016cited by this paper
• RAS/Effector Interactions from Structural and Biophysical Perspective.

  2016cited by this paper
• The Necrosome Promotes Pancreas Oncogenesis via CXCL1 and Mincle Induced Immune Suppression

  2016cited by this paper
• Membrane potential modulates plasma membrane phospholipid dynamics and K-Ras signaling

  2015cited by this paper
• RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients

  2015cited by this paper
• Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?

  2015cited by this paper
• Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

  2015cited by this paper
• A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells

  2015cited by this paper
• Peroxiredoxin 1 Promotes Pancreatic Cancer Cell Invasion by Modulating p38 MAPK Activity

  2015cited by this paper
• Targeting cancer cell metabolism in pancreatic adenocarcinoma

  2015cited by this paper
• Micro-RNA-155 is induced by K-Ras oncogenic signal and promotes ROS stress in pancreatic cancer

  2015cited by this paper
• K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling.

  2015cited by this paper
• Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells.

  2015cited by this paper
• Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up.

  2015cited by this paper
• Ras nanoclusters: Versatile lipid-based signaling platforms.

  2015cited by this paper
• MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?

  2015cited by this paper
• The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas

  2015cited by this paper
• K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif

  2015cited by this paper
• High-Affinity Interaction of the K-Ras4B Hypervariable Region with the Ras Active Site

  2015cited by this paper
• The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)

  2015cited by this paper
• The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-κB and RalB signaling pathways.

  2015cited by this paper
• Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer.

  2015cited by this paper
• Inhibition of Ras signalling reduces neutrophil infiltration and tissue damage in severe acute pancreatitis.

  2015cited by this paper
• nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

  2015cited by this paper
• p38 MAPK in Pancreatic Cancer: Finding a Protective Needle in the Haystack

  2014cited by this paper
• Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer

  2014cited by this paper
• Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.

  2014cited by this paper
• Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations.

  2014cited by this paper
• Downstream of Mutant KRAS, the Transcription Regulator YAP Is Essential for Neoplastic Progression to Pancreatic Ductal Adenocarcinoma

  2014cited by this paper
• MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer.

  2014cited by this paper
• Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange

  2014cited by this paper
• DUSP1 Is a Novel Target for Enhancing Pancreatic Cancer Cell Sensitivity to Gemcitabine

  2014cited by this paper
• Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function

  2014cited by this paper
• Modeling the role of G12V and G13V Ras mutations in the Ras-GAP-catalyzed hydrolysis reaction of guanosine triphosphate.

  2014cited by this paper
• Dragging ras back in the ring.

  2014cited by this paper
• An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition

  2014cited by this paper
• Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α

  2014cited by this paper
• Drugging the undruggable RAS: Mission Possible?

  2014cited by this paper
• Mucins and tumor resistance to chemotherapeutic drugs.

  2014cited by this paper
• MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies.

  2014cited by this paper
• The RAS subfamily Evolution – tracing evolution for its utmost exploitation

  2014cited by this paper
• Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.

  2014cited by this paper
• KRAS: feeding pancreatic cancer proliferation.

  2014cited by this paper
• Small-molecule modulation of Ras signaling.

  2014cited by this paper
• Targeting the K-Ras - JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation

  2014cited by this paper
• miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer

  2014cited by this paper
• Of autophagy and in vivo pancreatic carcinogenesis: the p53 status matters!

  2014cited by this paper
• Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer.

  2014cited by this paper
• Critical role of NF-κB in pancreatic cancer

  2014cited by this paper
• K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

  2013cited by this paper
• Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance

  2013cited by this paper
• Faculty Opinions recommendation of K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.

  2013cited by this paper
• Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling

  2013cited by this paper
• Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer.

  2013cited by this paper
• Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells

  2013cited by this paper
• Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions.

  2013cited by this paper
• Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway

  2013cited by this paper
• Tumor adaptation and resistance to RAF inhibitors

  2013cited by this paper
• Pancreatic cancer.

  2013cited by this paper
• Mutant KRAS is a druggable target for pancreatic cancer

  2013cited by this paper
• KRAS mutations and their correlation with survival of patients with advanced pancreatic cancer.

  2013cited by this paper
• Targeting the alternative NF-κB pathway in pancreatic cancer: a new direction for therapy?

  2013cited by this paper
• Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance.

  2013cited by this paper
• ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells

  2013cited by this paper
• Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression.

  2013cited by this paper
• Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma

  2013cited by this paper
• p53 status determines the role of autophagy in pancreatic tumour development

  2013cited by this paper
• Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.

  2012cited by this paper
• The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

  2012cited by this paper
• What we have learned about pancreatic cancer from mouse models.

  2012cited by this paper
• Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.

  2012cited by this paper
• K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo

  2012cited by this paper
• Targeting the Ras–ERK pathway in pancreatic adenocarcinoma

  2012cited by this paper
• Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy

  2012cited by this paper
• Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice

  2012cited by this paper
• Tif1γ suppresses murine pancreatic tumoral transformation by a Smad4-independent pathway.

  2012cited by this paper
• Abstract 4163: Determination of synthetic lethal interactions in KRAS oncogene dependent cancer cells reveals novel therapeutic targeting strategies

  2012cited by this paper
• Autophagy in pancreatic cancer pathogenesis and treatment.

  2012cited by this paper
• Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice.

  2012cited by this paper
• Mouse models of pancreatic cancer.

  2012cited by this paper
• The crystal structure of the catalytic domain of the NF-κB inducing kinase reveals a narrow but flexible active site.

  2012cited by this paper
• Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer

  2012cited by this paper
• Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

  2012cited by this paper
• Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia.

  2012cited by this paper
• Transcriptional regulation of the interleukin-11 gene by oncogenic Ras.

  2012cited by this paper
• KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.

  2012cited by this paper
• An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice.

  2012cited by this paper
• Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation.

  2012cited by this paper
• Biological and Prognostic Relevance of Mitogen-Activated Protein Kinases in Pancreatic Adenocarcinoma

  2012cited by this paper
• The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

  2012cited by this paper

• microRNAs in pancreatic cancer: Key modulators of tumor progression and therapeutic resistance.

  2026cites this paper
• Inflammation and Type 1 interferon signaling in pancreatic adenocarcinoma: Insights into inflammasome driven crosstalk and therapeutic advances.

  2025cites this paper
• Pancreatic cancer-derived extracellular vesicles enhance chemoresistance by delivering KRASG12D protein to cancer-associated fibroblasts

  2025cites this paper
• Combination of KRAS ASO and RIG-I agonist in extracellular vesicles transforms the tumor microenvironment towards effective treatment of KRAS-dependent cancers

  2025cites this paper
• Efficacy of CRISPR-Cas9 gene editing for targeting KRAS mutations in pancreatic cancer: a systematic review

  2025cites this paper
• KRAS Mutations in Cancer: From Molecular Insights to Therapeutic Strategies.

  2025cites this paper
• The Associations Between the TyG Index and the Risk of Cancer—A Systematic Review and Meta‐Analysis

  2025cites this paper
• Inhibition of the Alternative Complement Pathway May Cause Secretion of Factor B, Enabling an Early Detection of Pancreatic Cancer.

  2024cites this paper
• Key genes and pathways in the molecular landscape of pancreatic ductal adenocarcinoma: A bioinformatics and machine learning study

  2024cites this paper
• A molecularly tailored closed-loop tumor cell energy nanodepleter for cancer starvation therapy

  2024cites this paper
• Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors.

  2024cites this paper
• KRAS Mutation Detection with (2S,4R)-4-[18F]FGln for Noninvasive PDAC Diagnosis

  2024cites this paper
• A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way.

  2024cites this paper
• An overview of recent advancements in small molecules suppression of oncogenic signaling of K-RAS: an updated review

  2024cites this paper
• Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer

  2023cites this paper
• Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.

  2023cites this paper
• Identification of calcium and integrin-binding protein 1 as a reprogrammed glucose metabolism mediator to restrict immune cell infiltration in the stromal compartment of pancreatic ductal adenocarcinoma

  2023cites this paper
• Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer

  2023cites this paper
• Aphanamixis polystachya: pharmacological benefits, health benefits and other potential benefits

  2023cites this paper
• Pancreatic Cancer in Chronic Pancreatitis: Pathogenesis and Diagnostic Approach

  2023cites this paper
• Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target

  2022cites this paper
• Proteomic characteristics of PM2.5-induced differentially expressed proteins in k-ras-silenced HBE cells

  2022cites this paper
• Prognostic Value and Correlation With Tumor Immune Infiltration of a Novel Metabolism-Related Gene Signature in Pancreatic Cancer

  2022cites this paper
• Moving towards dawn: KRas signaling and treatment in pancreatic ductal adenocarcinoma.

  2022cites this paper
• The Roles of MicroRNA in Pancreatic Cancer Progression

  2022cites this paper
• Pan-KRAS inhibitors suppress proliferation through feedback regulation in pancreatic ductal adenocarcinoma

  2022cites this paper
• Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors

  2022cites this paper
• Current Pathology Model of Pancreatic Cancer

  2022cites this paper
• Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy

  2022cites this paper
• Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy

  2022cites this paper
• Identification of significant prognostic risk markers for pancreatic ductal adenocarcinoma: a bioinformatic analysis.

  2022cites this paper
• SIRT6 promotes ferroptosis and attenuates glycolysis in pancreatic cancer through regulation of the NF-κB pathway

  2022cites this paper
• The mechanism and progress of ferroptosis in pancreatic cancer.

  2022cites this paper
• DNA Polymerase Theta Plays a Critical Role in Pancreatic Cancer Development and Metastasis

  2022cites this paper
• Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening

  2022cites this paper
• Emerging Potential Mechanism and Therapeutic Target of Ferroptosis in PDAC: A Promising Future

  2022cites this paper
• DFMO Improves Survival and Increases Immune Cell Infiltration in Association with MYC Downregulation in the Pancreatic Tumor Microenvironment

  2021cites this paper
• Uncovering key targets of success for immunotherapy in pancreatic cancer

  2021cites this paper
• Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers

  2021cites this paper
• Highlights on the Role of KRAS Mutations in Reshaping the Microenvironment of Pancreatic Adenocarcinoma

  2021cites this paper
• MicroRNAs as biomarkers and perspectives in the therapy of pancreatic cancer

  2021cites this paper
• Intraductal Papillary Mucinous Carcinoma Versus Conventional Pancreatic Ductal Adenocarcinoma: A Comprehensive Review of Clinical-Pathological Features, Outcomes, and Molecular Insights

  2021cites this paper
• Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors

  2021cites this paper
• Ral GTPase–activating protein regulates the malignancy of pancreatic ductal adenocarcinoma

  2021cites this paper
• Non‐coding RNAs underlying the pathophysiological links between type 2 diabetes and pancreatic cancer: A systematic review

  2021cites this paper
• Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer

  2020cites this paper
• Celecoxib combined with salirasib strongly inhibits pancreatic cancer cells in 2D and 3D cultures

  2020cites this paper
• Pancreatic Cancer and Its Microenvironment—Recent Advances and Current Controversies

  2020influential citation
• An albumin-binding domain and targeting peptide-based recombinant protein and its enediyne-integrated analogue exhibit directional delivery and potent inhibitory activity on pancreatic cancer with K-ras mutation

  2020cites this paper
• The role of asparagine synthetase on nutrient metabolism in pancreatic disease.

  2020cites this paper
• Adenocarcinoma de pâncreas - revisão de literatura

  2020cites this paper
• Cell Type-Specific p38δ Targeting Reveals a Context-, Stage-, and Sex-Dependent Regulation of Skin Carcinogenesis

  2019cites this paper
• Targeting EphA2 with miR‐124 mediates Erlotinib resistance in K‐RAS mutated pancreatic cancer

  2019cites this paper
• Cell-free microRNAs as Non-invasive Diagnostic and Prognostic Bio- markers in Pancreatic Cancer

  2019cites this paper
• Prognostic value and prospective molecular mechanism of miR-100-5p in hepatocellular carcinoma: A comprehensive study based on 1,258 samples

  2019cites this paper
• MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators

  2019cites this paper
• PDS5B regulates cell proliferation and motility via upregulation of Ptch2 in pancreatic cancer cells.

  2019cites this paper
• Myc instructs and maintains pancreatic adenocarcinoma phenotype

  2019cites this paper
• Potential four-miRNA signature associated with T stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co-expression analysis

  2018cites this paper
• The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF–ERK signaling

  2018cites this paper
• Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence.

  2018cites this paper
• Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition

  2018cites this paper
• Nogo-B receptor promotes epithelial-mesenchymal transition in non-small cell lung cancer cells through the Ras/ERK/Snail1 pathway.

  2018cites this paper
• miR-135b-5p Promotes migration, invasion and EMT of pancreatic cancer cells by targeting NR3C2.

  2017cites this paper
• Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing

  2017cites this paper
• Bcl-3 deficiency promotes cancer stem cell-ness and metastatic properties in pancreatic ductal adenocarcinoma

  2017cites this paper
• Mucins in pancreatic cancer: biological role, implications in carcinogenesis and applications in diagnosis and therapy.

  2017cites this paper
• Non-BRCA1/2 Breast Cancer Susceptibility Genes: A New Frontier with Clinical Consequences for Plastic Surgeons

  2017cites this paper